Citation: Yingying Chen, Qiang Zeng, Bingyang Chu, Zhigang Liu, Xue Wei, Mengran Chen, Peipei Yang, Minghai Tang, Ting Niu, Yongqian Jia, Ying Qu, Zhiyong Qian. Melphalan-loaded methoxy poly(ethylene glycol)-poly(D, L-lactide) copolymer nanomicelles in the treatment of multiple myeloma[J]. Chinese Chemical Letters, ;2023, 34(9): 108133. doi: 10.1016/j.cclet.2023.108133 shu

Melphalan-loaded methoxy poly(ethylene glycol)-poly(D, L-lactide) copolymer nanomicelles in the treatment of multiple myeloma

Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China

quying1988@126.com

zhiyongqian@scu.edu.cn

Received Date: 13 August 2022
Revised Date: 27 December 2022
Accepted Date: 3 January 2023
Available Online: 5 January 2023

Figures(4)

Multiple myeloma (MM) is the second most common hematological tumor characterized by the proliferation of monoclonal plasma cells. Melphalan (MEL) is commonly used in the treatment of MM and is especially essential for patients undergoing autologous stem cell transplantation (ASCT). Although many drugs for MM have been developed in recent years, chemotherapy followed by ASCT remains the optimal option. Melphalan, the backbone of the conditioning regimen, brings severe toxicities at a high dose. Nanodrug delivery systems enable drugs to be highly effective and have low toxicity. In this study, methoxy poly(ethylene glycol)-poly(D, L-lactide) copolymer (MPEG-PDLLA) was chosen to encapsulate melphalan, and the characteristics, effectiveness, and safety of MEL/MPEG-PDLLA in vitro and in vivo were investigated. MEL/MPEG-PDLLA showed slow release and was easily engulfed by MM cells despite a result of the antitumor assay comparable to that of free melphalan in vitro. The in vivo results showed that MEL/MPEG-PDLLA could significantly alleviate tumor burden and prolong survival time without increasing the toxicity to vital organs. In addition, MEL/MPEG-PDLLA could significantly reduce the damage to the intestinal mucosa caused by melphalan. In conclusion, MEL/MPEG-PDLLA shows improved antitumor activity and has the potential to alleviate pains of MM patients undergoing ASCT.
- Melphalan,
- Multiple myeloma,
- MPEG-PDLLA,
- Nanomicelle
1. [1]
  F. Esma, M. Salvini, R. Troia, et al., Expert Opin. Pharmacother. 18 (2017) 1127–1136. doi: 10.1080/14656566.2017.1349102
2. [2]
  P. Yang, Y. Qu, M. Wang, et al., MedComm 3 (2022) e146. doi: 10.1002/mco2.146
3. [3]
  C. Costello, F.E. Davies, G. Cook, et al., Future Oncol. 15 (2019) 1411–1428. doi: 10.2217/fon-2019-0013
4. [4]
  G. Sarosy, B. Leyland-Jones, P. Soochan, B.D. Cheson, J. Clin. Oncol. 6 (1988) 1768–1782. doi: 10.1200/JCO.1988.6.11.1768
5. [5]
  I.A. Taha, R.A. Ahmad, D.W. Rogers, J. Pritchard, H.J. Rogers, Cancer Chemother. Pharmacol. 10 (1983) 212–216.
6. [6]
  D.L. Betcher, N. Burnham, J. Pediatr. Oncol. Nurs. 7 (1990) 35–36. doi: 10.1177/104345429000700110
7. [7]
  P. Falco, S. Bringhen, I. Avonto, et al., Expert Rev. Anticancer Ther. 7 (2007) 945–957. doi: 10.1586/14737140.7.7.945
8. [8]
  E.A. Stadtmauer, M.C. Pasquini, B. Blackwell, et al., J. Clin. Oncol. 37 (2019) 589–597. doi: 10.1200/jco.18.00685
9. [9]
  R. Al Hamed, A.H. Bazarbachi, F. Malard, J.L. Harousseau, M. Mohty, Blood Cancer J. 9 (2019) 44. doi: 10.1038/s41408-019-0205-9
10. [10]
  M. Martino, A.G. Recchia, G. Console, et al., Expert Opin Orphan Drugs 5 (2017) 875–887. doi: 10.1080/21678707.2017.1387050
11. [11]
  R. Liu, D. Li, F. Sun, et al., Stem Cell. Res. Ther. 11 (2020) 470. doi: 10.1186/s13287-020-01984-1
12. [12]
  A. Olivieri, L. Corvatta, M. Montanari, et al., Bone Marrow Transplant. 21 (1998) 1049–1053. doi: 10.1038/sj.bmt.1701217
13. [13]
  P. Moreau, T. Facon, M. Attal, et al., Blood 99 (2002) 731–735. doi: 10.1182/blood.V99.3.731
14. [14]
  J.J. Lahuerta, M.V. Mateos, J. Martínez-López, et al., Haematologica 95 (2010) 1913–1920. doi: 10.3324/haematol.2010.028027
15. [15]
  M. Blanes, J.J. Lahuerta, J.D. González, et al., Biol. Blood Marrow Transplant. 19 (2013) 69–74. doi: 10.1016/j.bbmt.2012.08.009
16. [16]
  P. Patel, A.L. Oh, M. Koshy, et al., Leuk. Lymphoma 59 (2018) 1666–1671. doi: 10.1080/10428194.2017.1390231
17. [17]
  Q. Bashir, P.F. Thall, D.R. Milton, et al., Lancet Haematol. 6 (2019) e266–e275. doi: 10.1016/S2352-3026(19)30023-7
18. [18]
  A. Mukhopadhyay, S. Basu, S. Singha, H.K. Patra, Research (Wash D C) 2018 (2018) 9712832.
19. [19]
  H. Tian, L. Lin, Z. Ba, et al., Chin. Chem. Lett. 32 (2021) 3665–3674. doi: 10.1016/j.cclet.2021.05.070
20. [20]
  P.C. Liang, Y.C. Chen, C.F. Chiang, et al., Int. J. Nanomedicine 11 (2016) 2021–2037.
21. [21]
  V.M. Alves, D. Hwang, E. Muratov, et al., Sci. Adv. 5 (2019) eaav9784. doi: 10.1126/sciadv.aav9784
22. [22]
  L. Chen, L. Tan, X. Zhang, et al., Int. J. Pharm. 495 (2015) 265–275. doi: 10.1016/j.ijpharm.2015.08.043
23. [23]
  M. Gou, K. Men, H. Shi, et al., Nanoscale 3 (2011) 1558–1567. doi: 10.1039/c0nr00758g
24. [24]
  D. Peer, J.M. Karp, S. Hong, et al., Nat. Nanotechnol. 2 (2007) 751–760. doi: 10.1038/nnano.2007.387
25. [25]
  Q. Zhou, C. Dong, W. Fan, et al., Biomaterials 240 (2020) 119902. doi: 10.1016/j.biomaterials.2020.119902
26. [26]
  D. Hu, O. Mezghrani, L. Zhang, et al., Int. J. Nanomedicine 11 (2016) 5125–5147. doi: 10.2147/IJN.S113469
27. [27]
  R.T. Liggins, H.M. Burt, Adv. Drug Deliv. Rev. 54 (2002) 191–202. doi: 10.1016/S0169-409X(02)00016-9
28. [28]
  A. Ouahab, N. Cheraga, V. Onoja, Y. Shen, J. Tu, Int. J. Pharm. 466 (2014) 233–245. doi: 10.1016/j.ijpharm.2014.03.009
29. [29]
  Y. Wang, H. Zhao, J. Peng, et al., J. Biomed. Nanotechnol. 12 (2016) 2011–2097. doi: 10.1080/10494820.2015.1073748
30. [30]
  L. Tan, J. Peng, Q. Zhao, et al., Theranostics 7 (2017) 2652–2672. doi: 10.7150/thno.19680
31. [31]
  Y. Hao, M. Dong, T. Zhang, et al., ACS Appl. Mater. Interfaces 9 (2017) 15317–15327. doi: 10.1021/acsami.7b03604
32. [32]
  J. Li, J. Wang, X. Zhang, X. Xia, C. Zhang, Int. J. Biol. Macromol. 141 (2019) 997–1003. doi: 10.1016/j.ijbiomac.2019.09.085
33. [33]
  J.C. Ramírez-Arroniz, E. Martínez Klimova, L.D. Pedro-Hernández, et al., Drug Dev. Ind. Pharm. 44 (2018) 1342–1349. doi: 10.1080/03639045.2018.1449857
34. [34]
  B. Chu, L. Zhang, Y. Qu, et al., Sci. Rep. 6 (2016) 34069. doi: 10.1038/srep34069
35. [35]
  X. Zheng, B. Kan, M. Gou, et al., Int. J. Pharm. 386 (2010) 262–267. doi: 10.1016/j.ijpharm.2009.11.014
1. [1]
  Ying Xu , Chengying Shen , Hailong Yuan , Wei Wu . Mapping multiple phases in curcumin binary solid dispersions by fluorescence contrasting. Chinese Chemical Letters, 2024, 35(9): 109324-. doi: 10.1016/j.cclet.2023.109324
2. [2]
  Tong Su , Yue Wang , Qizhen Zhu , Mengyao Xu , Ning Qiao , Bin Xu . Multiple conductive network for KTi₂(PO₄)₃ anode based on MXene as a binder for high-performance potassium storage. Chinese Chemical Letters, 2024, 35(8): 109191-. doi: 10.1016/j.cclet.2023.109191
3. [3]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
4. [4]
  Xin Jiang , Han Jiang , Yimin Tang , Huizhu Zhang , Libin Yang , Xiuwen Wang , Bing Zhao . g-C₃N₄/TiO_2-X heterojunction with high-efficiency carrier separation and multiple charge transfer paths for ultrasensitive SERS sensing. Chinese Chemical Letters, 2024, 35(10): 109415-. doi: 10.1016/j.cclet.2023.109415

Get Citation

PDF

XML

Metrics

PDF Downloads(4)
Abstract views(200)
HTML views(8)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Address：Zhongguancun North First Street 2,100190 Beijing, PR China Tel: +86-010-82449177-888

DownLoad: Full-Size Img PowerPoint

Return